# Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

> **NCT07284472** · PHASE2,PHASE3 · RECRUITING · sponsor: **Exciva GmbH** · enrollment: 300 (estimated)

## Conditions studied

- Agitation Associated With Alzheimer's Disease Dementia

## Interventions

- **DRUG:** EXV-802
- **DRUG:** Placebo
- **DRUG:** EXV-801

## Key facts

- **NCT ID:** NCT07284472
- **Lead sponsor:** Exciva GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-02
- **Primary completion:** 2029-01
- **Final completion:** 2029-02
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07284472

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07284472, "Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07284472. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*